Protagenic Therapeutics I... (PTIXW)
0.00
-0.01 (-100.00%)
At close: Apr 17, 2025, 9:54 AM
0.00
-13.35%
Pre-market: Apr 21, 2025, 07:00 AM EDT
Company Description
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
The company was founded in 2016 and is based in New York, New York.
Protagenic Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dr. Garo H. Armen Ph.D. |
Contact Details
Address: 149 Fifth Avenue New York, New York United States | |
| Website | http://www.protagenic.com |
Stock Details
| Ticker Symbol | PTIXW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N111 |
| ISIN Number | US74365N1110 |
| Employer ID | 06-1390025 |
| SIC Code | 7389 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer & Secretary |
| Dr. Andrew Slee Ph.D. | Chief Operating Officer |
| Dr. Garo H. Armen Ph.D. | Co-Founder & Executive Chairman of the Board |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 10, 2025 | DEF 14A | Filing |
| Feb 27, 2025 | PRE 14A | Filing |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |